Schott plans 24/7 RTF syringe production at US plant

Related tags Syringe Us

The US arm of packaging giant Schott has added ready-to-fill (RTF) glass syringe manufacturing capacity at its facility in Lebanon, Pennsylvania in a $14m (€9.4m) expansion designed to meet growing demand.

Schott predicted that North American demand for RTF manufacturing will increase eight to 10 per cent a year, driven by the growth of key therapeutic markets for diseases like diabetes and cancer.

The firm, which already manufactures vials, ampoules and cartridges at the Lebanon plant, said it will produce up to 270,000 RTF syringes a day when fully operational and added that it will create 40 new jobs over the next 12 months.

Schott plans to begin round-the-clock production in the next two years and added that a further $30m will be invested to boost manufacturing capacity at the site.

The firm, which claims the expansion makes it only the second company to make RTF syringes in the US, did not respond to in-PharmaTechnologist’s request for additional information.

Related news

Show more

Related products

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us


View more